Page 26 - Read Online

Page 60 Ding et al. J Transl Genet Genom 2021;5:50-61 I http://dx.doi.org/10.20517/jtgg.2020.01

Ethical approval and consent to participate
This study was approved by the City of Hope (COH) Institutional Review Board (IRB07244).

Consent for publication
Documents of consent for publication are available if requested.

Copyright
© The Author(s) 2021.

REFERENCES
1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2017. National Cancer Institute. Bethesda, MD. 2019,
https://seer.cancer.gov/csr/1975_2017/, November 2019 SEER data submission(posted to the SEER web site, April 2020.
2. Li J, German R, King J, et al. Recent trends in prostate cancer testing and incidence among men under age of 50. Cancer Epidemiol
2012;36:122-7.
3. Bleyer A, Spreafico F, Barr R. Prostate cancer in young men: An emerging young adult and older adolescent challenge. Cancer
2020;126:46-57.
4. Kucera R, Pecen L, Topolcan O, et al. Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first
century and 3PM dimensional solutions. EPMA J 2020;11:399-418.
5. Kinnear NJ, Kichenadasse G, Plagakis S, et al. Prostate cancer in men aged less than 50 years at diagnosis. World J Urol 2016;34:1533-9.
6. Mahal AR, Butler S, Franco I, et al. Conservative management of low-risk prostate cancer among young versus older men in the United
States: Trends and outcomes from a novel national database. Cancer 2019;125:3338-46.
7. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. N Engl
J Med 2018;379:2319-29.
8. Boström PJ, Bjartell AS, Catto JW, et al. Genomic Predictors of Outcome in Prostate Cancer. Eur Urol 2015;68:1033-44.
9. Ding Y, Wu H, Warden C, et al. Gene Expression Differences in Prostate Cancers between Young and Old Men. PLoS Genet
2016;12:e1006477.
10. Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA. Prostate cancer in young men: an important clinical entity. Nat Rev Urol
2014;11:317-23.
11. Steurer S, Mayer PS, Adam M, et al. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer. Eur
Urol 2014;66:978-81.
12. Weischenfeldt J, Simon R, Feuerbach L, et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in
early-onset prostate cancer. Cancer Cell 2013;23:159-70.
13. Zhao SG, Jackson WC, Kothari V, et al. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers
and therapeutic targets in prostate cancer. Prostate Cancer Prostatic Dis 2015;18:229-36.
14. Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for assessing differential expression in microarray experiments.
Bioinformatics 2005;21:2067-75.
15. Erho N, Crisan A, Vergara IA, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis
following radical prostatectomy. PLoS One 2013;8:e66855.
16. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl
Acad Sci U S A 2002;99:6567-72.
17. Wang S, Zhu J. Improved centroids estimation for the nearest shrunken centroid classifier. Bioinformatics 2007;23:972-9.
18. Blagus R, Lusa L. Improved shrunken centroid classifiers for high-dimensional class-imbalanced data. BMC Bioinformatics 2013;14:64.
19. Karnes RJ, Bergstralh EJ, Davicioni E, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in
an at risk patient population. J Urol 2013;190:2047-53.
20. Klein EA, Yousefi K, Haddad Z, et al. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-
negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur Urol 2015;67:778-86.
21. Den RB, Feng FY, Showalter TN, et al. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after
postoperative radiation therapy. Int J Radiat Oncol Biol Phys 2014;89:1038-46.
22. Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 2017;18:220.
23. Wilcox R. Introduction to Robust Estimation and Hypothesis Testing. 4th ed. Academic press; 2016.
24. Jegerlehner S, Chiolero A, Aujesky D, et al; NICER Working Group. Recent incidence and surgery trends for prostate cancer: Towards an
attenuation of overdiagnosis and overtreatment? PLoS One 2019;14:e0210434.
25. Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol 2014;65:1046-55.
26. Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason
grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol 2014;66:550-60.
27. Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in
patients with prostate cancer: a retrospective study. The Lancet Oncology 2011;12:245-55.
28. Murphy LC, Simon SL, Parkes A, et al. Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer